THE-THINGS-INDUSTRIES
19.9.2023 16:01:33 CEST | Business Wire | Press release
The Things Industries, a global leader in LoRaWAN® Internet of Things (IoT) solutions, has announced 1.5 million devices connected to its robust network server infrastructure, The Things Stack, marking a new milestone in its journey towards operational excellence and product leadership in the LoRaWAN ecosystem. This and more announcements are being celebrated during the flagship event - The Things Conference, organized by The Things Industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230919065625/en/
The Things Industries has reached 1.5 million connected devices to its LoRaWAN Network Server (Graphic: Business Wire)
The company has emerged as a product leader and is widely respected for its operational excellence, uptime, and product completeness. Among its clients and partners are numerous Fortune 500 companies, utility companies, IoT product scale-ups, and a diverse range of system integrators.
This achievement underscores the company's commitment to product leadership and operational excellence in the market of LoRaWAN solution management software, and the ability to scale IoT projects for The Things Industries’ customers and partners. The Things Industries’ LoRaWAN platform is a global product that can be used in every industry vertical.
The recent report by Beecham Research validates the continued growth of LoRaWAN and the adoption across the world. As a global leader in the market of LoRaWAN network management software providers, The Things Industries validates these findings by seeing wide range adoption of the standard on its platform.
The Things Industries serve the market with its leading platform, The Things Stack Cloud, a managed LoRaWAN network server with advanced features and cloud capability that provides industry-leading uptimes with unlimited scalability. With the cloud capability, free and seamless upgrades come included.
The Things Conference, the company's flagship user event, will showcase the broad adoption and usage of the LoRaWAN standard and The Things Stack Cloud platform. The conference will feature over 100 device manufacturers, 110 speakers sharing their IoT experiences, and more than 60 concrete solutions with detailed business cases will be showcased. The Things Conference takes place on 21 and 22 September 2023 from 9 AM to 5 PM Central European Summer Time. The event will be streamed live worldwide.
Wienke Giezeman, CEO of The Things Industries, commented, "The Things Conference is a gathering where we celebrate hard-won successes in the LoRaWAN user space. IoT is a challenging field, and the level of innovation on display is growing every year. I anticipate engaging with the 1,000+ IoT innovators at our event."
About The Things Industries
Founded in 2015, The Things Industries is a leading provider of LoRaWAN IoT solutions, designed to offer secure and efficient connectivity. With a focus on driving efficiency and sustainability, the company estimates that its platform contributes to over $1 billion in efficiency gains for its customers.
For those interested in building IoT solutions based on LoRaWAN, The Things Industries offers a use case selector for product and service recommendations. To get started with the secure LoRaWAN Network Server, visit https://www.thethingsindustries.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919065625/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom